Ligand Pharmaceuticals Incorporated reports results for the quarter ended June 30 - Earnings Summary

Ligand Pharmaceuticals Incorporated

06/08/2026 14:32

Ligand Pharmaceuticals Incorporated LGND.OQ reported quarterly adjusted earnings of $2.37​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $1.60.  The mean expectation of ten analysts for the quarter was for earnings of $1.84 per share. Wall Street expected results to range from $1.38  to $2.03 per share.
Revenue rose 134.6% to $111.73 million from a year ago; analysts expected $60.76 million. 
Ligand Pharmaceuticals Incorporated's reported EPS for the quarter was $2.22​.
The company reported quarterly net income of $48.51 million.
Ligand Pharmaceuticals Incorporated shares had fallen by 4.3% this quarter and gained 60.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 7.3% in the last three months.​ 
In the last 30 days, five analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Ligand Pharmaceuticals Incorporated is $337.50, about 10.3% above its last closing price of $302.57
This summary was machine generated from LSEG data August 6 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
1.84
2.37
Beat
Mar. 31 2026 
1.82
1.63
Missed
Dec. 31 2025 
1.56
2.02
Beat
Sep. 30 2025 
1.93
3.09
Beat